anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: Aging is related to deterioration of bodily and neural functions, leading to various disorders and symptoms, including the development of dementia, hearing loss, or tinnitus. Understanding how these phenomena are intertwined and how aging affects those is crucial for prevention and the future development of interventions.
METHODS: We utilized the UK Biobank which includes a total of 502,382 participants between 40 and 70 years old. We used logistic regression models and cox proportional hazard models and compared hazard ratios.
RESULTS: The odds of reporting tinnitus in the older age group (i.e., older than 58 years) were increased by 53.6 % and a one decibel increase in the speech-reception thresholds enhanced the odds for tinnitus by 13.0 %. For our second analysis regarding hearing loss, the risk of dementia increased by 14.0 % with an increase by one decibel in the speech-reception threshold score. In terms of aging, each additional year increased the risk by 17.3 %. Tinnitus alone showed a significant influence with a hazard ratio of 52.1 %, however, when adding hearing loss, age and various covariates, the effect vanished.
CONCLUSION: Findings confirm that tinnitus is indeed related to aging, but presumably independent of the aging processes accompanying the development of dementia. This highlights the urge to further investigate the impact of aging on neural processes that are relevant for alterations in the auditory systems (e.g., leading to the development of tinnitus or hearing loss) as well as for increased vulnerability in terms of neurodegenerative diseases.
The invention discloses a traditional Chinese medicinecomposition for treating nephritis and a preparation method thereof, belonging to the field of traditional Chinese medicine treatment of nephritis. The invention first disclosesthe traditional Chinese medicinecomposition for treating nephritis. The traditional Chinese medicinecomposition comprises the following components: fructus cnidii, radix paeoniae alba, radix rubiae, herba lysimachiae, apricot kernel and Tokyo violet herb. The active pharmaceutical ingredients rhizoma seu radix notopterygii, frankincense and herba artemisiae capillariae are added to the traditional Chinese medicine composition to realize better functions of regulating qi and activating blood and dispelling wind and relieving pain. The comparison result of clinical effects proves that an obvious synergistic effect between the fructus cnidii, radix paeoniae alba, radix rubiae, herba lysimachiae, apricot kernel and Tokyo violet herb and the rhizoma seu radix notopterygii, frankincense and herba artemisiae capillariaeis realized, the cure rate of chronic nephritis reaches 86%, and total effective rate is up to 98%. The traditional Chinese medicine composition disclosed by the invention has the advantages of reasonable compatibility, good treatment effect and no toxic or side effect; and the preparation method is simple and has a good application prospect.
The experimental group is comprised of participants with OSA and hypertension \[either able bodied (Aim 1) or with spinal cord injury (Aim 2)\] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2) = 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
The invention discloses a cefazolin ester and a preparation method thereof as well as an oral antibiotic preparation. The molecular structural formula of the cefazolin ester is as shown in (I) in descriptions. The preparation method of the cefazolin ester comprises preparation of cefazolin ester acid-base salt and esterification reaction of cefazolin ester acid-base salt and carbonic acid-1-iodine ethyl ester ochxl cyclohexyl ester. The oral antibiotic preparation contains the cefazolin ester, the structural formula of which is as shown in (I). The cefazolin ester has the activity of cefazolin medicines and proper lipid/water partition coefficients and is suitable for drug administration of gastrointestinal tracts. The preparation method has the advantages that reaction conditions are easy to control, the process is simple, and the product yield is high. The oral antibiotic preparation has a good medicine effect and is safe and convenient to use; the occurrence rate of antibiotic misuse can be effectively reduced; and meanwhile, the selective range of oral antibiotics at home is expanded.
Trichloroethylene (TCE) is an industrial solvent used in degreasing, dry cleaning, and numerous other medical and industrial processes. It is a ubiquitous environmental contaminant of drinking water and is present in many EPA Superfund sites. TCE is a rodent carcinogen but its carcinogenicity in humans is unclear. There is some evidence for an elevation in liver and kidney cancers and somewhat more convincing evidence of an association with non-Hodgkin lymphoma (NHL) in epidemiological studies of occupationally exposed cohorts. Overall, the carcinogenicity of TCE and its regulation is a matter of continuing debate despite an extensive database of in vitro and in vivo animal studies and several cohort and case-control studies. IARC categorizes TCE as a probable human carcinogen. In order to address questions about TCE's potential carcinogenicity and mechanism of action in humans, we propose to conduct a cross-sectional study of early biologic effect biomarkers of genotoxicity and immunotoxicity in 45 workers exposed to greater than 25 ppm TCE, 30 workers exposed to 10-25 ppm TCE, and 45 unexposed controls in Guangdong Province, China. We will assess TCE exposure level quantitatively, collect other exposure information through a questionnaire, collect biological samples, and assay a series of biomarkers of susceptibility, intermediate and early biologic effects. Our primary goal is to determine if TCE exposure increases chromosomal aberrations in peripheral lymphocytes, with a secondary goal of determining if TCE alters levels of key cytokines in plasma and changes lymphocyte subset ratios. In addition, our collaborators at UC Berkeley will apply a new generation of cytogenetic and molecular techniques to study TCE's ability to cause specific types of chromosomal aberrations that have been associated with NHL and related hematological malignancies as well as the impact of TCE on mRNA expression and the proteome. The work will compliment previous and ongoing OEEB studies of populations exposed to TCE and has the potential to make an important contribution to what little is known about the early biologic effects of TCE in humans.
A method for automatically generating a note summarizing a conversation between a patient and a healthcare provider is disclosed. A workstation is provided with a tool for rendering an audio recording of the conversation and a display for displaying a transcript of the audio recording obtained from a speech-to-text engine. The display of the workstation includes first transcript region for display of the transcript and a second note region for simultaneous displaying of elements of a note summarizing the conversation. Words or phrases in the transcript related to medical topics relating to the patient are extracted with the aid of a trained machine learning model. The extracted words or phrases are highlighted in the transcript and displayed in the note region. Links or a mapping between the extracted words or phrases in the note region and the portions of the transcript from which the extracted words or phrases originated are provided whereby the source and accuracy of the extracted words or phrases in the note region can be verified by a user.
Understanding patient goals and preferences is critical in the context of complex conditions such as chronic pain. This need may be especially pronounced for Black patients, who experience significant health and healthcare disparities. The primary aim of this study was to describe the treatment goals and preferences of Black veterans with chronic musculoskeletal pain who were enrolled in the intervention arm of a randomized controlled trial testing a coaching intervention. In the coaching sessions, participants (n = 106) identified their most important pain-related treatment goals and preferences. Participants' top treatment goals were to improve physical functioning (61%), increase engagement in valued activities (45%), and reduce pain intensity (37%). Most participants (73%) preferred non-pharmacological treatments (eg, physical therapy, exercise, acupuncture, yoga). The 17% of participants who identified medications as a preferred treatment demonstrated higher levels of depression and anxiety compared to those who did not. Approximately 42% and 21% of participants stated a preference to avoid pharmacological and surgical pain treatments, respectively. Black patients with chronic pain prioritize improving physical functioning and pain intensity in service of increasing their engagement in exercise, work, relationships, and leisure activities. Also, in the current study, patients expressed a clear preference for non-pharmacological pain treatments. Future research should investigate ways to improve communication of goals and preferences with providers and facilitate access to non-pharmacological treatments for Black patients with chronic pain. PERSPECTIVE: This article describes the treatment goals and preferences of Black veterans with chronic pain. Most patients prioritized goals to improve physical functioning, pain severity, and participation in valued activities. Patients primarily preferred non-pharmacological treatments. This emphasizes the need for clear communication with Black patients regarding pain-related goals and non-pharmacological treatment options.
FIELD: biologically active polymers. SUBSTANCE: invention relates to dendrimeric polymer conjugates containing at least one dense star- shaped polymer associated with at least one unit of at least one biological response modifier. Conjugate can have a target indicator being at the same time biologically active agent. Dense star-shaped polymers are used as carriers for agricultural, pharmaceutical, and other materials. EFFECT: essentially extended possibilities of biologically active polymers. 132 cl, 62 dwg, 25 tbl, 77 ex
During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
BACKGROUND AND PURPOSE: Non-alcoholic fatty liver disease (NAFLD) has increasing worldwide prevalence, fuelled by rising obesity rates, and weight reduction is the mainstay of its management. We sought to study the effect of bariatric surgery, the most effective long-term treatment for obesity and associated metabolic disorders, on liver function in people with obesity.
METHODS: We performed a retrospective longitudinal cohort study of 511 patients who had undergone bariatric surgery (71 sleeve gastrectomy and 440 gastric bypass) over 60 months of follow-up. Patients were stratified into groups based on their baseline alanine aminotransferase (ALT) into Group A (ALT < 40 U/L) and Group B (ALT > 40 U/L). Postoperative follow-up weight loss, liver function tests, HbA1c, blood pressure and lipid profiles were collected.
FINDINGS: Bariatric surgery resulted in nadir total weight loss of 33.1% by 24 months (p < 0.001) with no significant difference between groups. In people with raised baseline ALT (Group B), ALT and gamma glutamyl transferase (GGT) levels decreased significantly by 4 months postoperatively (p < 0.001) and sustained over 60 months of follow-up. There was also significant and sustained reduction in HbA1c, blood pressure, total cholesterol, and non-HDL cholesterol overall with no differences between groups.
CONCLUSIONS: Bariatric surgery results in significant weight loss, improves liver function tests and metabolic outcomes in people with obesity. Bariatric surgery could be a therapeutic consideration for patients with NAFLD associated with severe obesity who have otherwise been unresponsive to conservative management.
DOB categorisation of Generation Y: 1st January 1981 - 31st December 1995. PGDiTs recruited from the local hospital will be stratified into generational groups according to their date of birth. The investigators anticipate on having approximately two focus groups per generation.
To allow users to use a measurement unit more properly.SOLUTION: The biological information measurement unit includes a body case 1a, a sensor attachment unit 3, a measuring unit 4, a control unit 5, a storage unit 6, a timepiece 7, and a battery 10. The sensor attachment unit 3 is provided in the body case 1a and has a sensor 2 attached thereto for measuring biological information. The measurement unit 4 is connected to the sensor attachment unit 3. The control unit 5 is connected to the measurement unit 4. The storage unit 6 is connected to the control unit 5. The timepiece 7 is connected to the control unit 5. The battery 10 is connected to the control unit 5. The control unit 5 has an improvement data acquisition unit 13 for acquiring measurement variation factor information for each measurement. The improvement data acquisition unit 13 calculates the time elapsed since charge is completed, using the last time when charge of the battery 10 is ended stored in the storage unit 6 and the current time of the timepiece 7.SELECTED DRAWING: Figure 2
The development and clinical implementation of catheter ablation of supraventricular tachycardia is one of the outstanding achievements of modern cardiovascular treatment. Over a period of less than 40 years, a curative and safe treatment strategy for almost all forms of atrial arrhythmias has been developed and implemented. German electrophysiologists and engineers have made a significant contribution to this truly outstanding success story in modern medicine. Their contributions should be appropriately acknowledged because without them, the development of ablation technology and its worldwide dissemination would not have been possible. Both the technological contributions and the medical-electrophysiological contributions were at the absolute forefront of worldwide developments and have made a significant contribution to the fact that today more than 500,000 patients with symptomatic and/or threatening cardiac arrhythmias can be successfully treated every year by use of catheter ablation. We would like to thank them all for their achievements.
IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.
Disclosed is a novel composition which has a function of accelerating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production accelerating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives of D-alanine or D-hydroxyproline and/or salts of D-alanine or D-hydroxyproline. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include but are not limited to photoaging, wrinkles, rough skin, fine wrinkles and dry skin. The composition may be used for an external preparation for the skin or food.
PROBLEM TO BE SOLVED: To embody sufficient tacky adhesives and the decreases the reshes of the skin and the pain at the time of peeling by constituting the tacky adhesive compsn. of an acrylic copolymer and aliphat. alcohol and composing the acrylic copolymer of 2-ethyl hexyl methacrulate and alkyl ester acrylate exclusive of the methactuylate. SOLUTION: This tacky adhesive compsn. for medical treatment consists of 88 to 99.5wt.%. acrylic copolymer and 0.5 to 20wt.% 12 to 20C aliphat. alcohol. The acrylic copolymer consist of the 2-ethyl hexylmethacrylate and the alkyl ester (meth) acrylate of 6 to 16C alkyl groups exclusive of the 2-ethyl hexyl methacylate as its constituting components and contains 40 to 90wt.% 2-ethyl hexyl methacrylate in the monomer components constituting the acrylic copolymer. Then, the higher alcohol is added to the acrylic copolymer, by which the stimuli on the skin are decreased. In addition, the tacky adhesive layer is softened, by which both properties of a hydrophilic property and hydrophobic property are imparted to the tacky adhesive compsn.
The invention provides amphiphilic compounds of the formula (I) Ch-(-L-Ar-(-AH)n)m (where Ch is a hydrophilic chelant moiety or a salt or a chelate thereof); each L is an optionally oxo substituted C2-25-alkylene linker wherein at least one CH2 moiety is replaced by a group X1 (e.g. L may include a chain sequence, an X1(CH2CH2X1)u (where u is a positive integer) such as X1CH2CH2X1, CH2X1CH2CH2X1CH2CH2X1, CH2X1CH2CH2X1CH2CH2X1CH2CH2X1, etc.), and wherein L is optionally interrupted by a metabolizable group M but with the provisos that the terminus of L adjacent Ch is CH¿2? and that the terminus of L adjacent Ar is X?1¿ or a CH¿2? group adjacent or separated by one CH2 from a group X?1¿ (thus, for example the L-Ar linkage may be L?1-X1-Ar, L1-CH¿2-Ar, L1-X1CH2-Ar or L1-X1CH2CH2-Ar, where L1 is the residue of L; each Ar is an aryl ring optionally substituted by or having fused thereto a further aryl ring; each AH is a protic acid group, preferably an oxyacid, e.g. a carbon, sulphur or phosphorus oxyacid or a salt thereof; each X1 is O, S, NR?1 or PR1¿, preferably no more than 3 X1 groups being present in L; each R1 is hydrogen, alkyl or aryl; and m and n are positive integers, m being for example 1 to 4, especially 1 or 2 and n being for example 1, 2 or 3) which are especially suited for use in diagnostic imaging of the hepatobiliary system.
We propose a nonparametric compound Poisson model for underreported count data that introduces a latent clustering structure for the reporting probabilities. The latter are estimated with the model's parameters based on experts' opinion and exploiting a proxy for the reporting process. The proposed model is used to estimate the prevalence of chronic kidney disease in Apulia, Italy, based on a unique statistical database covering information on m = 258 municipalities obtained by integrating multisource register information. Accurate prevalence estimates are needed for monitoring, surveillance, and management purposes; yet, counts are deemed to be considerably underreported, especially in some areas of Apulia, one of the most deprived and heterogeneous regions in Italy. Our results agree with previous findings and highlight interesting geographical patterns of the disease. We compare our model to existing approaches in the literature using simulated as well as real data on early neonatal mortality risk in Brazil, described in previous research: the proposed approach proves to be accurate and particularly suitable when partial information about data quality is available.
Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
To evaluate the safety and efficacy of the 250 mg dose, 10 day regimen of levofloxacin, 567 patients with uncomplicated UTI, mild-to-moderate cUTI, and mild-to-moderate AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the US from June 1993 to January 1995 comparing levofloxacin 250 mg orally once daily for 10 days (285 patients) with ciprofloxacin 500 mg orally twice daily for 10 days (282 patients). Patients with a resistant pathogen, recurrent UTI, women over age 55 years, and with an indwelling catheter were initially excluded, prior to protocol amendment which took place after 30% of enrollment. Microbiological efficacy was measured by bacteriologic eradication of the baseline organism(s) at 1–12 days post-therapy in patients with a pathogen identified at baseline.

The bacteriologic cure rates overall for levofloxacin and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in Table 18.

* 1–9 days posttherapy for 30% of subjects enrolled prior to a protocol amendment; 5–12 days posttherapy for 70% of subjects.

† The mITT population included patients who had a pathogen isolated at baseline. Patients with missing response were counted as failures in this analysis.

‡ The Microbiologically Evaluable population included mITT patients who met protocol-specified evaluability criteria.
Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.